Stargardt macular dystrophy and evolving therapies

References

• Rotenstreich Y, Fishman GA, Anderson RJ. Visual acuity loss and clinical observations in a large series of patients with Stargardt disease. Ophthalmology. 2003;110:1151–1158.
   PubMed Web of Science ®Google Scholar
• Fishman GA, Farber M, Patel BS, et al. Visual acuity loss in patients with Stargardt’s macular dystrophy. Ophthalmology. 1987;94:809–814.
   PubMed Web of Science ®Google Scholar
• Lambertus S, van Huet RA, Bax NM, et al. Early-onset Stargardt disease: phenotypic and genotypic characteristics. Ophthalmology. 2015;122:335–344.
   PubMed Web of Science ®Google Scholar
• Lambertus S, Lindner M, Bax NM, et al. Progression of late-onset Stargardt disease. Invest Ophthalmol Vis Sci. 2016;57:5186–5191.
   PubMedGoogle Scholar
• Eagle RC Jr., Lucier AC, Bernardino VB Jr., et al. Retinal pigment epithelial abnormalities in fundus flavimaculatus: a light and electron microscopic study. Ophthalmology. 1980;87:1189–1200.
   PubMed Web of Science ®Google Scholar
• Hadden OB, Gass JD. Fundus flavimaculatus and Stargardt’s disease. Am J Ophthalmol. 1976;82:527–539.
   PubMed Web of Science ®Google Scholar
• Paavo M, Lee W, Allikmets R, et al. Photoreceptor cells as a source of fundus autofluorescence in recessive Stargardt disease. J Neurosci Res. 2018. doi: 10.1002/jnr.24252. [Epub ahead of print].
   PubMedGoogle Scholar
• Uliss AE, Moore AT, Bird AC. The dark choroid in posterior retinal dystrophies. Ophthalmology. 1987;94:1423–1427.
   PubMed Web of Science ®Google Scholar
• Gomes NL, Greenstein VC, Carlson JN, et al. A comparison of fundus autofluorescence and retinal structure in patients with Stargardt disease. Invest Ophthalmol Vis Sci. 2009;50:3953–3959.
   PubMed Web of Science ®Google Scholar
• Fujinami K, Lois N, Mukherjee R, et al. A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. Invest Ophthalmol Vis Sci. 2013;54:8181–8190.
   PubMed Web of Science ®Google Scholar
• Brunk UT, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med. 2002;33:611–619.
   PubMed Web of Science ®Google Scholar
• Gray DA, Woulfe J. Lipofuscin and aging: a matter of toxic waste. Sci Aging Knowledge Environ. 2005;2005:re1.
   PubMedGoogle Scholar
• Katz ML, Robison WG Jr. What is lipofuscin? Defining characteristics and differentiation from other autofluorescent lysosomal storage bodies. Arch Gerontol Geriatr. 2002;34:169–184.
   PubMed Web of Science ®Google Scholar
• de Jong PT. Age-related macular degeneration. N Engl J Med. 2006;355:1474–1485.
   PubMed Web of Science ®Google Scholar
• Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res. 2005;80:595–606.
   PubMed Web of Science ®Google Scholar
• Lee W, Noupuu K, Oll M, et al. The external limiting membrane in early-onset Stargardt disease. Invest Ophthalmol Vis Sci. 2014;55:6139–6149.
   PubMed Web of Science ®Google Scholar
• Kong X, Strauss RW, Cideciyan AV, et al. Visual acuity change over 12 months in the prospective progression of atrophy secondary to Stargardt disease (ProgStar) study: progStar report number 6. Ophthalmology. 2017;124:1640–1651.
   PubMed Web of Science ®Google Scholar
• Schonbach EM, Wolfson Y, Strauss RW, et al. Macular sensitivity measured with microperimetry in Stargardt disease in the progression of atrophy secondary to Stargardt disease (ProgStar) study: report No. 7. JAMA Ophthalmol. 2017;135:696–703.
   PubMed Web of Science ®Google Scholar
• Strauss RW, Munoz B, Ho A, et al. Progression of Stargardt disease as determined by fundus autofluorescence in the retrospective progression of Stargardt disease study (ProgStar Report No. 9). JAMA Ophthalmol. 2017;135:1232–1241.
   PubMed Web of Science ®Google Scholar
• Strauss RW, Munoz B, Ho A, et al. Incidence of atrophic lesions in Stargardt disease in the progression of atrophy secondary to Stargardt disease (ProgStar) Study: report no. 5. JAMA Ophthalmol. 2017;135:687–695.
   PubMed Web of Science ®Google Scholar
• Weng J, Mata NL, Azarian SM, et al. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt’s disease from the phenotype in abcr knockout mice. Cell. 1999;98:13–23.
   PubMed Web of Science ®Google Scholar
• Boyer NP, Higbee D, Currin MB, et al. Lipofuscin and N-retinylidene-N-retinylethanolamine (A2E) accumulate in retinal pigment epithelium in absence of light exposure: their origin is 11-cis-retinal. J Biol Chem. 2012;287:22276–22286.
   PubMed Web of Science ®Google Scholar
• Sparrow JR, Fishkin N, Zhou J, et al. A2E, a byproduct of the visual cycle. Vision Res. 2003;43:2983–2990.
   PubMed Web of Science ®Google Scholar
• Lamb LE, Simon JD. A2E: a component of ocular lipofuscin. Photochem Photobiol. 2004;79:127–136.
   PubMed Web of Science ®Google Scholar
• Suter M, Reme C, Grimm C, et al. Age-related macular degeneration. The lipofusion component N-retinyl-N-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. J Biol Chem. 2000;275:39625–39630.
   PubMed Web of Science ®Google Scholar
• Finnemann SC, Leung LW, Rodriguez-Boulan E. The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium. Proc Natl Acad Sci USA. 2002;99:3842–3847.
   PubMed Web of Science ®Google Scholar
• Saari JC. Vitamin A metabolism in rod and cone visual cycles. Annu Rev Nutr. 2012;32:125–145.
   PubMed Web of Science ®Google Scholar
• Lorenz B, Gyurus P, Preising M, et al. Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. Invest Ophthalmol Vis Sci. 2000;41:2735–2742.
   PubMed Web of Science ®Google Scholar
• Scholl H, Strauss RW, Singh MS, et al. Emerging therapies for inherited retinal degeneration. Sci Transl Med. 2016;8:368.
   Web of Science ®Google Scholar
• Quazi F, Molday RS. ATP-binding cassette transporter ABCA4 and chemical isomerization protect photoreceptor cells from the toxic accumulation of excess 11-cis-retinal. Proc Natl Acad Sci USA. 2014;111:5024–5029.
   PubMed Web of Science ®Google Scholar
• Mata NL, Radu RA, Clemmons RC, et al. Isomerization and oxidation of vitamin a in cone-dominant retinas: a novel pathway for visual-pigment regeneration in daylight. Neuron. 2002;36:69–80.
   PubMed Web of Science ®Google Scholar
• Imai H, Kefalov V, Sakurai K, et al. Molecular properties of rhodopsin and rod function. J Biol Chem. 2007;282:6677–6684.
   PubMed Web of Science ®Google Scholar
• Wang JS, Kefalov VJ. The cone-specific visual cycle. Prog Retin Eye Res. 2011;30:115–128.
   PubMed Web of Science ®Google Scholar
• Kaufman Y, Ma L, Washington I. Deuterium enrichment of vitamin A at the C20 position slows the formation of detrimental vitamin A dimers in wild-type rodents. J Biol Chem. 2011;286:7958–7965.
   PubMed Web of Science ®Google Scholar
• Ma L, Kaufman Y, Zhang J, et al. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J Biol Chem. 2011;286:7966–7974.
   PubMed Web of Science ®Google Scholar
• Charbel Issa P, Barnard AR, Herrmann P, et al. Rescue of the Stargardt phenotype in ABCA4 knockout mice through inhibition of vitamin A dimerization. Proc Natl Acad Sci U S A. 2015;112:8415–8420.
   PubMed Web of Science ®Google Scholar
• Petrukhin K. Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment. Drug Discov Today Ther Strateg. 2013;10:e11–e20.
   PubMedGoogle Scholar
• Holz FG, Sadda SR, Busbee B, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. Jama Ophthalmol. 2018;136(6):666–667.
   PubMed Web of Science ®Google Scholar
• Maeda A, Golczak M, Chen Y, et al. Primary amines protect against retinal degeneration in mouse models of retinopathies. Nat Chem Biol. 2011;8:170–178.
   PubMed Web of Science ®Google Scholar
• Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology. 2014;121:693–701.
   PubMed Web of Science ®Google Scholar
• Radu RA, Mata NL, Nusinowitz S, et al. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt’s macular degeneration. Proc Natl Acad Sci USA. 2003;100:4742–4747.
   PubMed Web of Science ®Google Scholar
• Weleber RG, Denman ST, Hanifin JM, et al. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol. 1986;104:831–837.
   PubMed Web of Science ®Google Scholar
• Sieving PA, Chaudhry P, Kondo M, et al. Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy. Proc Natl Acad Sci USA. 2001;98:1835–1840.
   PubMed Web of Science ®Google Scholar
• Kubota R, Boman NL, David R, et al. Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina. 2012;32:183–188.
   PubMed Web of Science ®Google Scholar
• Kong J, Kim SR, Binley K, et al. Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy. Gene Ther. 2008;15:1311–1320.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Novack RL, Csaky KG, et al. Phase ii, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration. Retina. 2015;35:1173–1183.
   PubMed Web of Science ®Google Scholar
• Berni R, Formelli F. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences. FEBS Lett. 1992;308:43–45.
   PubMed Web of Science ®Google Scholar
• Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci. 2005;46:4393–4401.
   PubMed Web of Science ®Google Scholar
• Samuel W, Kutty RK, Nagineni S, et al. N-(4-hydroxyphenyl)retinamide induces apoptosis in human retinal pigment epithelial cells: retinoic acid receptors regulate apoptosis, reactive oxygen species generation, and the expression of heme oxygenase-1 and Gadd153. J Cell Physiol. 2006;209:854–865.
   PubMed Web of Science ®Google Scholar
• Turton JA, Willars GB, Haselden JN, et al. Comparative teratogenicity of nine retinoids in the rat. Int J Exp Pathol. 1992;73:551–563.
   PubMed Web of Science ®Google Scholar
• Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina. 2013;33:498–507.
   PubMed Web of Science ®Google Scholar
• Dobri N, Qin Q, Kong J, et al. A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis. Invest Ophthalmol Vis Sci. 2013;54:85–95.
   PubMed Web of Science ®Google Scholar
• Zhou J, Kim SR, Westlund BS, et al. Complement activation by bisretinoid constituents of RPE lipofuscin. Invest Ophthalmol Vis Sci. 2009;50:1392–1399.
   PubMed Web of Science ®Google Scholar
• Zhou J, Jang YP, Kim SR, et al. Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci USA. 2006;103:16182–16187.
   PubMed Web of Science ®Google Scholar
• Berchuck JE, Yang P, Toimil BA, et al. All-trans-retinal sensitizes human RPE cells to alternative complement pathway-induced cell death. Invest Ophthalmol Vis Sci. 2013;54:2669–2677.
   PubMed Web of Science ®Google Scholar
• Radu RA, Hu J, Yuan Q, et al. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration. J Biol Chem. 2011;286:18593–18601.
   PubMed Web of Science ®Google Scholar
• Cao S, Wang JC, Gao J, et al. CFH Y402H polymorphism and the complement activation product C5a: effects on NF-kappaB activation and inflammasome gene regulation. Br J Ophthalmol. 2016;100:713–718.
   PubMed Web of Science ®Google Scholar
• Lenis TL, Sarfare S, Jiang Z, et al. Complement modulation in the retinal pigment epithelium rescues photoreceptor degeneration in a mouse model of Stargardt disease. Proc Natl Acad Sci USA. 2017;114:3987–3992.
   PubMed Web of Science ®Google Scholar
• Ophthotech Provides Update on Zimura® Complement Programs for Treatment of Eye Diseases. Accessed from: https://www.businesswire.com/news/home/20170919005345/en/Ophthotech-Update-Zimura%C2%AE-Complement-Programs-Treatment-Eye.
   Google Scholar
• Experts insights: will ophthotech continue its Zimura development program? Accessed from: https://www.clinicaltrialsarena.com/news/clinical-trials-arena/expert-insights-will-ophthotech-continue-its-zimura-development-program-5947727-2/
   Google Scholar
• Moore NA, Morral N, Ciulla TA, et al. Gene therapy for inherited retinal and optic nerve degenerations. Expert Opin Biol Ther. 2018;18(1):37–49.
   Web of Science ®Google Scholar
• Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3:879–889.
   PubMed Web of Science ®Google Scholar
• Yu-Wai-Man P. Genetic manipulation for inherited neurodegenerative diseases: myth or reality? Br J Ophthalmol. 2016;100:1322–1331.
   PubMed Web of Science ®Google Scholar
• Li Q, Miller R, Han PY, et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis. 2008;14:1760–1769.
   PubMed Web of Science ®Google Scholar
• Han Z, Conley SM, Naash MI. Gene therapy for Stargardt disease associated with ABCA4 gene. Adv Exp Med Biol. 2014;801:719–724.
   PubMed Web of Science ®Google Scholar
• Binley K, Widdowson P, Loader J, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Invest Ophthalmol Vis Sci. 2013;54:4061–4071.
   PubMed Web of Science ®Google Scholar
• Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. Graefes Arch Clin Exp Ophthalmol. 2017;255:1057–1062.
   PubMed Web of Science ®Google Scholar
• Han Z, Conley SM, Makkia RS, et al. DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice. J Clin Invest. 2012;122:3221–3226.
   PubMed Web of Science ®Google Scholar
• Amit M, Carpenter MK, Inokuma MS, et al. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. Dev Biol. 2000;227:271–278.
   PubMed Web of Science ®Google Scholar
• Bracha P, Moore NA, Ciulla TA. Induced pluripotent stem cell-based therapy for age-related macular degeneration. Expert Opin Biol Ther. 2017;17:1113–1126.
   PubMed Web of Science ®Google Scholar
• Lund RD, Wang S, Klimanskaya I, et al. Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats. Cloning Stem Cells. 2006;8:189–199.
   PubMedGoogle Scholar
• Lu B, Malcuit C, Wang S, et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Stem Cells. 2009;27:2126–2135.
   PubMed Web of Science ®Google Scholar
• Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet. 2015;385:509–516.
   PubMed Web of Science ®Google Scholar
• Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849–860.
   PubMed Web of Science ®Google Scholar